Cetuximab may be beneficial beyond progression in certain patients with mCRC
the ONA take:
According to new findings presented at the ESMO 17th World Congress on Gastrointestinal Cancer in Barcelona, Spain, researchers have found that continuing second-line cetuximab beyond progression following first-line chemotherapy and an anti-epidermal growth factor receptor (EGFR) monoclonal antibody is beneficial for patients with metastatic colorectal cancer who do not have KRAS, NRAS, BRAF, or PIK3CA gene mutations.
For the phase II study, researchers enrolled 340 patients with metastatic colorectal cancer and KRAS exon 2 wild-type tumors. All participants received first-line treatment with FOLFIRI plus cetuximab until unacceptable toxicity or disease progression. Those who experienced disease progression were then randomly assigned 1:1 to receive second-line FOLFOX plus cetuximab or FOLFOX alone.
Results showed that patients with quadruple wild-type metastatic colorectal cancer had significantly improved progression-free survival, improved overall survival, and improved response rates with the addition of second-line cetuximab. These patients were most likely to have an EGFR-dependent tumor.
The authors note that further studies are warranted to confirm these findings in a larger patient population.
Continuing second-line cetuximab beyond progression following first-line chemo and an anti-EGFR monoclonal antibody is beneficial for quadruple wild-type metastatic
Sign Up for Free e-newsletters
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer
- Better Postoperative Outcomes With RAMIE for Esophageal Cancer
- Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|